-
公开(公告)号：US20230285356A1
公开(公告)日：2023-09-14
申请号：US17977920
申请日：2022-10-31
Applicant: Sunovion Pharmaceuticals Inc.
Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.
-
公开(公告)号：US20220340588A1
公开(公告)日：2022-10-27
申请号：US17145548
申请日：2021-01-11
Applicant: Sunovion Pharmaceuticals Inc. , PGI Drug Discovery LLC
Inventor： Linghong XIE , Michele L.R. HEFFERNAN , Philip Glyn JONES , Taleen G. HANANIA
IPC: C07D493/04 , C07D311/76 , C07D313/08 , C07D307/87
Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.
-
公开(公告)号：US20220323409A1
公开(公告)日：2022-10-13
申请号：US17616460
申请日：2020-06-04
Applicant: SUNOVION PHARMACEUTICALS INC.
Inventor： Takumi ASADA , Gerald R. GALLUPPI , Seth Cabot HOPKINS , Megumi MARUYAMA , Siriporn TOONGSUWAN , Yuki TSUSHIMA
Abstract: Provided are modified release compositions in a solid oral dosage form comprising racemic amisulpride, or pharmaceutically acceptable salts thereof, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens.
-
公开(公告)号：US11406786B2
公开(公告)日：2022-08-09
申请号：US16390908
申请日：2019-04-22
Applicant: SUNOVION PHARMACEUTICALS INC.
Inventor： Michael Segal , Nathan Abel , Spencer Brown , Everett Crosland , Francisco Javier de Ana Arbeloa , Thomas Goodin , Joseph Gordon , Michael Metz , Daniel Nelson , Jae Hong Park , Sean Scanlon , Janis Skujins , Jennet Toyjanova
Abstract: Described herein are devices, systems and methods for monitoring the use of a nebulized medication, such as can be administered using a nebulizer. These can be used for monitoring a patient undergoing treatment for COPD and improve compliance to the recommended therapy. Monitored parameters include flow, humidity and acceleration and provide data as to the quantity and quality of nebulizer use.
-
公开(公告)号：US20220185799A1
公开(公告)日：2022-06-16
申请号：US17452786
申请日：2021-10-29
Applicant: Sunovion Pharmaceuticals Inc. , PGI Drug Discovery LLC
Inventor： Linghong XIE , Philip Glyn JONES , Kerry L. SPEAR , Noel Aaron POWELL , Taleen G. HANANIA , Vadim ALEXANDROV
IPC: C07D405/04 , C07D405/14 , C07D413/14 , C07D493/04 , C07D413/04
Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
-
Patent Agency Ranking
公开(公告)号：US20220161983A1
公开(公告)日：2022-05-26
申请号：US17437454
申请日：2020-03-12
Applicant: Sunovion Pharmaceuticals Inc.
Inventor： Julie A. CARDIN , Edward Emmett CHAPDELAINE
Abstract: Disclosed are packages for dispensing a product, the package including: a first layer; a second layer; a tab seal zone in which the first layer is joined to the second layer by a seal, the tab seal zone defining a first tab and a second tab; a first perforation in the first layer and a second perforation in the second layer, the first perforation defining a tear path in the first layer and the second perforation defining a tear path in the second layer, wherein at least one of the first and second perforations at least partially defines a boundary separating the first tab and the second tab; and a fold guide located in the tab seal zone, the fold guide indicating a fold line that intersects the first perforation and the second perforation across the boundary separating the first tab and the second tab.
-
公开(公告)号：US11312554B2
公开(公告)日：2022-04-26
申请号：US17029468
申请日：2020-09-23
Applicant: Sunovion Pharmaceuticals Inc.
Inventor： Julie A. Cardin , Edward Emmett Chapdelaine , Steven A. Rau
IPC: B65D75/58 , B65B9/00 , B65D75/50 , B65D75/30 , B65D75/52 , B65B7/02 , B65B9/02 , B65B61/00 , B65B61/06
Abstract: Embodiments include a package for containing and dispensing a product. The package includes first and second layers; a product seal zone where the first layer is joined to the second layer, the product seal zone having an inner perimeter that defines an unsealed pouch area for containing the product and an outer perimeter; and a header zone adjacent to the outer perimeter of the product seal zone. The header zone includes a first tab; a second tab; a first tab-cut in the first layer within an unsealed portion of the header zone; and a second tab-cut in the second layer within the unsealed portion of the header zone. Other embodiments are also included herein.
-
公开(公告)号：US20210386689A1
公开(公告)日：2021-12-16
申请号：US17286155
申请日：2019-10-30
Applicant: Sunovion Pharmaceuticals Inc.
Inventor： Jing LIN
IPC: A61K31/135 , A61K31/137 , A61K31/536 , A61K31/55 , A61K31/496 , A61K31/427
Abstract: Provided herein are methods of treating central nervous system (CNS) disorders (e.g., Binge Eating Disorder (BED), Attention-Deficit/Hyperactivity Disorder (ADHD), etc.) with a dasotraline therapy while avoiding adverse drug interactions.
-
公开(公告)号：US11186564B2
公开(公告)日：2021-11-30
申请号：US16322278
申请日：2016-08-04
Applicant: Sunovion Pharmaceuticals Inc.
Inventor： Michele L. R. Heffernan , Larry Wendell Hardy , Scott P. Brown , Lee W. Herman
IPC: C07D211/22 , C07D401/08 , C07D401/14 , C07D401/06 , C07D401/12 , C07D405/06 , C07D471/04 , C07D487/10 , C07D491/107 , C07D311/22 , C07D217/24 , C07D223/08 , C07D235/12 , C07D237/14 , C07D413/06 , C07D241/04 , C07D243/08 , C07D471/08 , C07D491/048 , C07D267/10 , C07D275/04 , C07D211/58 , C07D403/06 , C07D405/12 , A61P25/28 , C07D417/04 , A61P25/18 , C07D513/04 , C07D211/42 , C07D295/104 , C07D207/36 , C07D213/81 , C07D491/20 , C07D249/12 , C07D221/20 , C07D295/088 , C07D311/58 , C07D207/12 , C07D211/44 , C07D265/30 , C07D277/66 , C07D295/027 , C07D295/073 , C07D295/096 , C07D295/108 , C07D307/83 , C07D311/08 , C07D413/08 , C07D471/10
Abstract: Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.
-
公开(公告)号：US20210315860A1
公开(公告)日：2021-10-14
申请号：US17097799
申请日：2020-11-13
Applicant: Sunovion Pharmaceuticals Inc.
Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.
-
-
-
-
-
-
-
-
-
Search Results
218
records
(took 0.024 seconds)
